Anemia in CKD Patient on Heamodialysis


Article PDF :

Veiw Full Text PDF

Article type :

Original Article

Author :

Hulsi Sahu | Atul Verma | Hemin Sahu

Volume :

2

Issue :

4

Abstract :

Anemia in chronic kidney disease is a prevalent and expensive problem in the United States, and it is well documented that anemia worsens as glomerular filtration rates decline. The complications of severe anemia in this patient population contribute significantly to their overall morbidity with increased cardiovascular complications, decreased quality of life, and increased dependence on transfusions to maintain adequate hemoglobin levels. Erythropoietin stimulating agents ESAs have revolutionized the treatment of anemia in this population, but there has been a great deal of controversy surrounding the quest for the ideal hemoglobin target. In addition, there are economic and practice management implications where anemia treatment is concerned, with ongoing refinement of Centers for Medicare and Medicaid Services bundled payments. One of the newest additions to the arsenal used to fight anemia in end stage renal disease patients is peginesatide Omontys , a synthetic, PEGylated, peptide based ESA that acts by stimulating the erythropoietin receptor. The role of peginesatide in the future treatment of anemia in chronic kidney disease remains uncertain, with new safety concerns being brought to attention as it emerges on the market, prompting a national recall. Hulsi Sahu | Atul Verma | Hemin Sahu "Anemia in CKD Patient on Heamodialysis" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-2 | Issue-4 , June 2018, URL: https://www.ijtsrd.com/papers/ijtsrd14601.pdf Paper URL: http://www.ijtsrd.com/other-scientific-research-area/other/14601/anemia-in-ckd-patient-on-heamodialysis/hulsi-sahu

Keyword :

anemia, chronic kidney disease, peginesatide
Journals Insights Open Access Journal Filmy Knowledge Hanuman Devotee Avtarit Wiki In Hindi Multiple Choice GK